Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, 7/29/11, politicians are in default, a dangerous tactical end-game

The 6 W’s: Who, what, where, when, why and what of it…

US stocks declined and Treasury prices rallied Friday after the government said the economy grew less than forecast in Q2/11and the ongoing political drama in Washington had the nation moving nearer to default. U.S. stock futures fell more on Friday.

A gauge of consumer sentiment fell in July to the lowest level since March 2009 on worse views for current and future economic conditions, according to the gauge from Thomson Reuters/University of Michigan released Friday.

Market reversal is happening, the NASDAQ is up at 11:20am and the DOW is still down but marginally!   The market seems to paralysed!

Stocks erased Friday losses to turn mostly higher after President Obama made another bid for compromise on the deficit and debt ceiling, arguing that while the House plan is moot, both sides are not that far apart.

Regenerative medicine/stem cell universe is at these bottoms … buying time!” as MY bellwethers begin to climb … CYTX (2 days in a tough market),  OPXA up $0.27, NeoStem (AMEX: NBS) is down post offering and acquisition but my gamble is still positive in the short/near term … on 7/29/11The NASDAQ is DOWN (-0.19%) to 2,761.11 having been up in the past hours.  The Dow is also DOWN (-0.60%) to 12,166.55.  

Who is UP … Athersys (NASDAQ:ATHX), BioMimetic (NASDAQ:BMTI), Bioheart (OTCPK:BHRT),  Cytori (NASDAQ:CYTX), Fibrocel (FSCS.OB), Neuralstem (AMEX: CUR),  Opexa (OPXA), Pluristem (NASDAQ:PSTI) and Osiris (NASDAQ:OSIR)  are up …

What’s new in the regenerative medicine/stem cell market … NOT MUCH, STEMD first to file Q2/11 … and it is Friday, end of month.

StemCells (STEMD) Q2/11 Results: A net loss of $4M or $0.29 per share: STEMD reported a net loss of $4M or $(0.29) per share, compared with a net loss of $4.6M or $(0.38) per share, forQ2/10. Loss from operations in Q2/11 was $7.09M which was relatively flat when compared to the $7.051M loss from operations inQ2/10. Q2/11 total revenue was $234K compared to $244K in Q2/10. Revenue from product sales was $185K which was a 153% increase compared to Q2/10. This growth was driven by both increased unit volumes and new products in the SC Proven media and reagents business. Revenue from licensing agreements and grants was $49K which was a 71% decrease compared to the previous year primarily due to the completion and termination of several projects funded by grants. Total operating expenses in Q2/11 were $7.272M, compared to $7.271M in Q2/10. Operating expenses in include $260K for severance and other expenses related to the reduction-in-force effected in May. In Q2/11 SG&A expenses of $2.103M were 8% lower compared to Q2/10. R&D expenses of $5.054M were 4% higher in Q2/11compared to Q2/10 as STEMD continued to prioritize its product development efforts. Other income was $3.055M compared to $2.441M in Q2/10. This increase was primarily due to a decrease in the estimated fair value of warrant liability. For the 6 month period ended 6/30/11, net cash used in operating activities was $13.131M which was 4% lower than the same period in 2010. Cash, cash equivalents and marketable securities at 6/30/11 totaled $15.657M compared with $19.899M at 12/31/10.